W

Walvax Biotechnology Co Ltd
SZSE:300142

Watchlist Manager
Walvax Biotechnology Co Ltd
SZSE:300142
Watchlist
Price: 14.46 CNY -5.61% Market Closed
Market Cap: 23.1B CNY
Have any thoughts about
Walvax Biotechnology Co Ltd?
Write Note

Relative Value

The Relative Value of one Walvax Biotechnology Co Ltd stock under the Base Case scenario is 22.69 CNY. Compared to the current market price of 14.46 CNY, Walvax Biotechnology Co Ltd is Undervalued by 36%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
22.69 CNY
Undervaluation 36%
Relative Value
Price
W
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
82
vs Industry
64
Median 3Y
9.7
Median 5Y
20.5
Industry
7.7
Forward
7.4
vs History
19
vs Industry
3
Median 3Y
99.7
Median 5Y
106.7
Industry
22.7
Forward
59
vs History
84
vs Industry
8
Median 3Y
37.5
Median 5Y
100
Industry
21.6
vs History
28
vs Industry
4
Median 3Y
74.2
Median 5Y
-137.2
Industry
25.2
vs History
87
vs Industry
44
Median 3Y
5.5
Median 5Y
8.8
Industry
2.5
vs History
80
vs Industry
59
Median 3Y
9.1
Median 5Y
19.6
Industry
7.7
Forward
6.6
vs History
77
vs Industry
57
Median 3Y
10.5
Median 5Y
22.7
Industry
9
vs History
57
vs Industry
6
Median 3Y
47.1
Median 5Y
61.1
Industry
4.2
Forward
18.5
vs History
57
vs Industry
6
Median 3Y
47.1
Median 5Y
61.1
Industry
4.1
Forward
23
vs History
79
vs Industry
9
Median 3Y
34.7
Median 5Y
95.9
Industry
5.7
vs History
9
vs Industry
0
Median 3Y
218.4
Median 5Y
-148.8
Industry
3.6
vs History
87
vs Industry
51
Median 3Y
5.4
Median 5Y
8.1
Industry
4.6

Multiples Across Competitors

Competitors Multiples
Walvax Biotechnology Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Walvax Biotechnology Co Ltd
SZSE:300142
23.2B CNY 6.9 172.3 48.8 48.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 083 264.3 -181 004.1 -219 796.6 -217 288.5
US
Abbvie Inc
NYSE:ABBV
312.7B USD 5.6 61.5 15.3 23.6
US
Amgen Inc
NASDAQ:AMGN
158.3B USD 4.9 37.4 17.5 33.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD 10.9 -241.6 24 25.2
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD 4 891.9 9.9 9.9
US
Epizyme Inc
F:EPE
94.1B EUR 1 849.9 -472 -514.1 -500.3
AU
CSL Ltd
ASX:CSL
133.6B AUD 5.9 32.9 20.3 25.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD 5.9 17.8 16.2 18
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.6 -58.7 -53
NL
argenx SE
XBRU:ARGX
34.5B EUR 18.5 -129.9 -104.5 -76.2
P/E Multiple
Earnings Growth
CN
W
Walvax Biotechnology Co Ltd
SZSE:300142
Average P/E: 202.3
172.3
107%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -181 004.1 N/A
US
Abbvie Inc
NYSE:ABBV
61.5
412%
US
Amgen Inc
NASDAQ:AMGN
37.4
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -241.6
42%
US
Gilead Sciences Inc
NASDAQ:GILD
891.9
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472 N/A
AU
CSL Ltd
ASX:CSL
32.9
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.6 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.9 N/A
EV/EBITDA Multiple
EBITDA Growth
CN
W
Walvax Biotechnology Co Ltd
SZSE:300142
Average EV/EBITDA: 21.7
48.8
113%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 796.6 N/A
US
Abbvie Inc
NYSE:ABBV
15.3
29%
US
Amgen Inc
NASDAQ:AMGN
17.5
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
43%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
16%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.1 N/A
AU
CSL Ltd
ASX:CSL
20.3
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
35%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.5 N/A
EV/EBIT Multiple
EBIT Growth
CN
W
Walvax Biotechnology Co Ltd
SZSE:300142
Average EV/EBIT: 26.3
48.8
87%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 288.5 N/A
US
Abbvie Inc
NYSE:ABBV
23.6
88%
US
Amgen Inc
NASDAQ:AMGN
33.1
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.2
44%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -500.3 N/A
AU
CSL Ltd
ASX:CSL
25.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.2 N/A

See Also

Discover More
Back to Top